. . . . . "cyclophosphamide" . . . "Avacopan" . . . "rituximab" . . . "GPA" . . . "glucocorticoids" . . . "granulomatosis with polyangiitis" . . . "polyang.itis" . "vasculitis" . . . "MPA" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "2022-10-13T13:48:59.639916"^^ . . " Avacopan is indicated for the adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis) in combination with standard therapy including glucocorticoids. In Europe, it is approved for the. treatment of adults with severe, active granulomatic polyang.itis (GPA/MPA) in. combination with rituximab or cyclophosphamide." . "2.3.0" . "RSA" . "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB" . "mktsnL/cZhj07z6wkSISbggRQl4OJRgJOTb1UQiJzMrPsxgZLsHOQvCSksUB+WEpLq9UbVxLu0J1Nzf1iwcFvaAzAxMBcY4UEb8kQrelTbAw9UsMHVnPx2b4Tn/QCnPgWf1opk2oeQpzg2leyDCEAopID/stcZCofHpKW4+nR8HxRiSb/uJyfpxnNAQnu/4+09ymLH20D5r7FLo/7bJGgEIMNYngG+GCQj5aP6KCl4KOZUPqBmX7PocF4yR4j279dKE0t6kg8vzXAJqSEo0d+d0DvTEtZoLXleGBj83eq09PfUwffeMSdvfweVIncxGmJ/f7f+zDcHgO5WM6qWVOxA==" . . "2022-10-13T13:48:59.639916"^^ . .